联合影像引导与抗体靶向α治疗在靶向免疫治疗前治疗实体瘤
研究在癌胚抗原(CEA)阳性同系乳腺癌和结肠癌的CEA转基因动物模型中,评估影像引导放疗(IGRT)联合低剂量靶向α治疗(TAT)及抗体靶向白细胞介素-2免疫细胞因子治疗的效果。分次IGRT(4次2.5 Gy)较单次10 Gy IGRT抗体瘤内穿透更好,联合低剂量TAT后肿瘤消退和生存更优;三联治疗在结肠癌模型获多数小鼠完全治愈并排斥所有再挑战,自然杀伤细胞及CD8阳性/干扰素-γ阳性细胞显著增加。
要点
- 分次IGRT(4次2.5 Gy)较单次10 Gy IGRT抗体瘤内穿透更好。
- IGRT联合低剂量TAT较单药免疫细胞因子治疗肿瘤消退和生存更优。
- 三联治疗获多数小鼠完全治愈并排斥所有再挑战。
核心结论
- 三联靶向治疗在实体瘤模型中疗效最佳,表现为肿瘤治愈、排斥肿瘤再挑战及免疫表型改变。
研究设计与样本
- 在CEA阳性同系乳腺癌和结肠癌的CEA转基因动物模型中,比较单次IGRT(10 Gy)与两种分次IGRT方案(4次2.5 Gy或4次3.65 Gy)联合或不联合低剂量TAT(37 kBq的225Ac-DOTA-anti-CEA)的效果。
主要发现
- 在乳腺癌模型的初步PET成像中,分次IGRT(4次2.5 Gy)较单次IGRT(10 Gy)抗体肿瘤穿透更好。
- IGRT联合低剂量TAT较未联合TAT者肿瘤消退和生存更优,4次2.5 Gy联合TAT组再挑战反应最佳。
- 结肠癌模型中,三联治疗(分次IGRT加低剂量TAT后免疫细胞因子治疗)使多数小鼠完全治愈并排斥所有再挑战。
- 治疗完成后2天免疫表型分析显示,三联治疗组自然杀伤细胞及CD8阳性/干扰素-γ阳性细胞显著增加。
- 肿瘤微环境变化表现为巨噬细胞减少及粒细胞和单核细胞浸润,是这些治疗的重要特征。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rationale of this study was to evaluate the efficacy of 3 types of targeted therapy for solid tumors, comprising image-guided radiation therapy (IGRT), low-dose targeted α-therapy (TAT), and antibody-targeted interleukin-2 immunocytokine therapy, with the expectation that the combination of 2 types of targeted radiation therapy would perform better than either monotherapy with immunocytokine therapy. Methods: Carcinoembryonic antigen (CEA)-positive syngeneic breast and colon tumors in CEA transgenic animals were treated with single-dose IGRT (10 Gy) and 2 different regimens of fractionated IGRT (4 doses of 2.5 Gy or 4 doses of 3.65 Gy), with and without low-dose TAT (37 kBq of 225Ac-DOTA-anti-CEA) to optimize doses and tumor models for the combination of 2 types of IGRT plus TAT with immunocytokine therapy. Results: In preliminary PET imaging in the breast cancer model, fractionated IGRT (4 doses of 2.5 Gy) provided better antibody tumor penetration than did single-dose IGRT (10 Gy). Similarly, tumor regression and survival were superior with IGRT when combined with low-dose TAT, followed with best rechallenge responses in the groups treated with 4 doses of 2.5 Gy combined with TAT. Since comparable results were obtained in the colon cancer model, triple therapy (fractionated IGRT plus low-dose TAT followed by immunocytokine therapy) was studied in the colon cancer model, demonstrating complete cures in the majority of mice and rejection of all rechallenges. When the study was repeated for immunophenotyping 2 d after the completion of therapy, significant increases in natural killer and CD8-positive/interferon-gamma-positive cells were observed with triple therapy. Moreover, the changes in the tumor microenvironment, as reflected by the reduction of macrophages and infiltration of granulocytes and monocytes, was an important feature of these therapies. The memory phenotypes of the CD8-positive cells in tumor-draining lymph nodes and tumors showed significant increases of T cells with central memory versus naïve phenotypes in untreated controls. Interestingly, in contrast to the spleens and tumor-draining lymph nodes, there was almost a complete lack of naïve CD4-positive cells in the control tumors, a situation that was reversed by all 3 types of therapy, with the combination of IGRT, TAT, and immunocytokine therapy exhibiting the highest increase. Conclusion: Triple targeted therapy had the best therapeutic effects in a solid tumor model as evidenced by tumor cures, rejection of tumor rechallenge, and immunophenotyping.
引用
- Kujawski M, Aniogo E, Wong P, et al. Combination Image-Guided and Antibody-Targeted α-Therapy Before Targeted Immunotherapy for Treatment of Solid Tumors. J Nucl Med. 2025. PMID: 40813233. doi:10.2967/jnumed.125.270266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。